Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban

Published 2018 View Full Article

Authors

Keywords

Atrial fibrillation, Ischemic stroke, Anticoagulants, Hemorrhage, Anticoagulant therapy, Diabetes mellitus, Heart failure, Stomach

Journal

PLoS One

Volume 13, Issue 4, Pages e0195950

Publisher

Public Library of Science (PLoS)

Online

2018-05-01

DOI

10.1371/journal.pone.0195950

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.